Global Cervical Intraepithelial Neoplasia Drugs Market – Industry Trends and Forecast to 2029

Market Analysis and Size

According to the American Cancer Society, roughly 13,800 new instances of invasive cervical cancer were expected to be diagnosed in the United States in 2020, with 4,290 women dying from the disease. Cervical intraepithelial neoplasia is frequently asymptomatic and is found by a standard Pap test. Cervical intraepithelial neoplasia is more common in women under the age of 30, but it can occur at any age. It is strongly linked to sexually transmit human papillomavirus (HPV) infection. Avastin, blemocin, bevacizumb, blenoxane, and others are the various types of drugs used to treat cervical intraepithelial neoplasia and distributed through various channels, including retail pharmacies hospitals pharmacies, and others.

Data Bridge Market Research analyses that the cervical intraepithelial neoplasia drugs market was valued at USD 525.75 million in 2021 and is expected to reach USD 857.13 million by 2029, registering a CAGR of 6.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Cervical intraepithelial neoplasia (CIN) is a disorder in which the cervix grows aberrant cells. Certain kinds of the human papillomavirus (HPV), as well as other environmental variables, can cause it, and it can sometimes lead to cervical cancer precursors. Cervical cancer is uncommon, although cervical intraepithelial neoplasia is not. The bottom section of the uterus that goes into the vaginal canal is known as the cervix. During childbirth, the cervix dilates to allow the foetus to pass through. The aberrant cells in cervical intraepithelial neoplasia aren't malignant. It can, however, grow into precancers or cancer if not monitored or treated in certain circumstances that require therapy. This condition is also termed as cervical dysplasia.

Cervical Intraepithelial Neoplasia Drugs Market Dynamics

Drivers

• Rise in the prevalence of human papillomavirus (HPV) infection

The surging prevalence of human papillomavirus (HPV) infection is a major factor driving the cervical intraepithelial neoplasia drugs market's growth rate. Cervical HPV infection is a sexually transmitted disease that increases the risk of cervical intraepithelial neoplasia. Only a small fraction of women infected with the virus may develop severe CIN or invasive cervical cancer. The HPV genotype that causes the infection is the most important determinant in determining whether the infection will develop to CIN.  Despite the fact that there are around 100 subtypes of HPV, only a tiny subset has been linked to cervical dysplasia and cancer. HPV subtypes are classified as cancer-causing or non-cancerous. Another important determinant in the development of CIN and, eventually, cancer is the virus's persistence in tissues. HPV infection can affect sexually active women of any age, but it is more common in adolescent and younger women. Women between the ages of 20 and 24 had the highest occurrence.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cervical intraepithelial neoplasia drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

• Surging frequency of human immunodeficiency virus (HIV) in women

The cervical intraepithelial neoplasia drugs market is growing due to the rising frequency of human immunodeficiency virus (HIV) in women. Cervical cancer is more common among HIV-positive women than in the general population. Nearly 18 million women in the world have tested positive for HIV. HIV impairs the immune system, increasing the risk of cervical cancer. Because the count of the protein CD4 decreases in HIV-positive women, they are more likely to be diagnosed with cervical intraepithelial neoplasia. A person with HIV is at the highest risk of getting cervical cancer, as per the study done by the National Cancer Institute.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cervical intraepithelial neoplasia drugs market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of cervical intraepithelial neoplasia drugs market. Along with this, the rising prevalence of cervical cancer and the dearth of awareness regarding diagnostic tests for prevention of invasive cancer will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by the rise in the number of research and development activities. This will provide beneficial opportunities for the cervical intraepithelial neoplasia drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cervical intraepithelial neoplasia drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the expiration of patented drugs and the introduction of generic version of drugs will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and the high cost associated with drugs will challenge the cervical intraepithelial neoplasia drugs market. Additionally, side effects linked with cervical intraepithelial neoplasia drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cervical intraepithelial neoplasia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cervical intraepithelial neoplasia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cervical intraepithelial neoplasia affects between 250,000 and 1 million cisgender women in the United States each year. The illness is most common in women of childbearing age, especially those between 25 and 35.

Cervical intraepithelial neoplasia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cervical Intraepithelial Neoplasia Drugs Market

The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had an impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The pandemic's lockdown has put a financial strain on the private healthcare industry in a number of countries. Outpatient visits, manpower, equipment, consumables, and other resources were reduced. Furthermore, the coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. Hence, the market is projected to stabilize in the future.

Recent Development

• In September 2021, the US Food and Drug Administration (FDA) had announced the approval of tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. It is a tissue factor-directed antibody as well as microtubule inhibitor conjugate used for the treatment of adults patients with recurrent or metastatic cervical cancer. 2 mg/kg (up to a maximum of 200 mg for patients ≥100 kg) is the recommended dose which is given as an intravenous infusion over 30 minutes every 3 weeks.

Global Cervical Intraepithelial Neoplasia Drugs Market Scope

The cervical intraepithelial neoplasia drugs market is segmented on the basis of disease type, treatment, indication, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Cervical Intraepithelial Neoplasia 1
• Cervical Intraepithelial Neoplasia 2
• Cervical Intraepithelial Neoplasia 3

Treatment

• Surgery
• Hysterectomy
• Cone biopsy
• Loop electrosurgical excision procedure (LEEP)
• Laser therapy
• Cryosurgery
• Medication
• Avastin
• Bevacizumb
• Blemocin
• Blenoxane
• Others
• Others

Indication

• Pre-malignant Lesions
• Early Invasive Stage
• Advanced Invasive Stage

Dosage Form

• Solution
• Powder
• Injection
• Cream
• Others

Route of Administration

• Intravenous
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cervical Intraepithelial Neoplasia Drugs Market Regional Analysis/Insights

The cervical intraepithelial neoplasia drugs market is analysed and market size insights and trends are provided by country, disease type, treatment, indication, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cervical intraepithelial neoplasia drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the cervical intraepithelial neoplasia drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, surging awareness and government-embedded reimbursement policies will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of human papillomavirus (HPV) infection in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cervical Intraepithelial Neoplasia Drugs Market Share Analysis

The cervical intraepithelial neoplasia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cervical intraepithelial neoplasia drugs market.

Some of the major players operating in the cervical intraepithelial neoplasia drugs market are:

• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Merck & Co., Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (US)
• Biocon (India)
• Amgen Inc. (US)
• Eli Lilly and Company (US)
• Allergan (Ireland)
• Hetero (India)
• Abbott (US)
• QIAGEN (Netherlands)
• Danaher (US)   

SKU-56243